#United States #New York #Securities Fraud #Rosen Law #Capricor

Opportunity for Capricor Investors

Capricor Therapeutics, Inc. (NASDAQ: CAPR) has recently found itself at the center of a significant legal dispute, raising concerns for its investors. The Rosen Law Firm, a globally recognized advocate for investor rights, is reaching out to individuals who acquired securities of Capricor within the timeframe of December 17, 2025 to July 26, 2026. Investors who experienced losses exceeding $100,000 during this period may have an opportunity to lead a class action lawsuit for potential recovery of their lost funds.

Important Deadlines

Investors are reminded that the deadline to apply as a lead plaintiff in this securities fraud lawsuit is September 28, 2026. Those who wish to take part in this legal action must act promptly, as registration must be completed by this date. Individuals can enroll in the class action by visiting Rosen Law Firm's website or reaching out directly to attorney Phillip Kim at 866-767-3653.

The Nature of the Allegations

The basis of the lawsuit lies in allegations that Capricor Therapeutics made materially false statements and failed to disclose critical information about its clinical product, Deramiocel. Particularly, the claims state that:

1. Capricor modified the statistical analysis plan that governs the examination of clinical trial data for Deramiocel.
2. The FDA had not approved these modifications prior to Capricor submitting its Biologics License Application (BLA) for the therapy.
3. Consequently, there was a risk that the FDA would determine the clinical data did not substantiate the effectiveness of Deramiocel.
4. Due to this lack of evidence, the path toward regulatory approval for treating Duchenne muscular dystrophy was jeopardized.
5. The company’s optimistic disclosures about its operational viability misled investors given these undisclosed risks.

When the authentic facts regarding these issues came to light, Capricor’s investors began to face significant financial damages as the stock value tumbled.

Why Choose Rosen Law Firm?

The Rosen Law Firm is uniquely positioned to represent investors in this class action lawsuit due to its extensive experience and a proven track record in handling securities class actions. Their history includes securing substantial settlements, with over $438 million retrieved for investors in just 2019 alone. The firm emphasizes the importance of selecting qualified counsel who not only have a wealth of experience but also are recognized within the legal community for their achievements in investor law.

Next Steps for Investors

For those considering participation in the Capricor class action lawsuit, it is critical to understand that no class has been certified as of yet. Potential members must choose their legal representatives promptly. Investors can opt to remain updated on the case without participating as a lead plaintiff. However, being a lead plaintiff can position one to direct the litigation on behalf of the entire group if so chosen. The firm encourages individuals to stay informed, as the ability to share in any possible settlements does not hinge solely on this lead role.

Stay Connected

To receive ongoing updates regarding the Capricor legal situation, interested parties can follow the Rosen Law Firm on its LinkedIn, Twitter, or Facebook pages.

As the deadline approaches, investors impacted by this situation should ensure they are taking timely actions to protect their interests and explore their legal options. The Rosen Law Firm stands by ready to guide them through this critical process.